|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALDH16A1 |
Gene summary for ALDH16A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALDH16A1 | Gene ID | 126133 |
| Gene name | aldehyde dehydrogenase 16 family member A1 | |
| Gene Alias | ALDH16A1 | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IZ83 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 126133 | ALDH16A1 | LZE4T | Human | Esophagus | ESCC | 7.00e-03 | 1.84e-01 | 0.0811 |
| 126133 | ALDH16A1 | LZE5T | Human | Esophagus | ESCC | 4.46e-03 | 5.33e-01 | 0.0514 |
| 126133 | ALDH16A1 | LZE7T | Human | Esophagus | ESCC | 1.83e-06 | 3.22e-01 | 0.0667 |
| 126133 | ALDH16A1 | LZE8T | Human | Esophagus | ESCC | 1.74e-06 | 1.83e-01 | 0.067 |
| 126133 | ALDH16A1 | LZE20T | Human | Esophagus | ESCC | 8.13e-06 | 3.32e-01 | 0.0662 |
| 126133 | ALDH16A1 | LZE22D1 | Human | Esophagus | HGIN | 9.71e-08 | 2.80e-01 | 0.0595 |
| 126133 | ALDH16A1 | LZE22T | Human | Esophagus | ESCC | 5.05e-08 | 4.37e-01 | 0.068 |
| 126133 | ALDH16A1 | LZE24T | Human | Esophagus | ESCC | 1.08e-12 | 3.74e-01 | 0.0596 |
| 126133 | ALDH16A1 | LZE21T | Human | Esophagus | ESCC | 2.39e-08 | 4.21e-01 | 0.0655 |
| 126133 | ALDH16A1 | P1T-E | Human | Esophagus | ESCC | 2.09e-21 | 8.22e-01 | 0.0875 |
| 126133 | ALDH16A1 | P2T-E | Human | Esophagus | ESCC | 1.25e-26 | 4.58e-01 | 0.1177 |
| 126133 | ALDH16A1 | P4T-E | Human | Esophagus | ESCC | 1.25e-18 | 4.74e-01 | 0.1323 |
| 126133 | ALDH16A1 | P5T-E | Human | Esophagus | ESCC | 1.13e-08 | 1.56e-01 | 0.1327 |
| 126133 | ALDH16A1 | P8T-E | Human | Esophagus | ESCC | 2.07e-48 | 8.33e-01 | 0.0889 |
| 126133 | ALDH16A1 | P9T-E | Human | Esophagus | ESCC | 4.24e-03 | 1.67e-01 | 0.1131 |
| 126133 | ALDH16A1 | P10T-E | Human | Esophagus | ESCC | 4.82e-36 | 5.83e-01 | 0.116 |
| 126133 | ALDH16A1 | P11T-E | Human | Esophagus | ESCC | 4.47e-15 | 6.23e-01 | 0.1426 |
| 126133 | ALDH16A1 | P12T-E | Human | Esophagus | ESCC | 3.50e-53 | 9.71e-01 | 0.1122 |
| 126133 | ALDH16A1 | P15T-E | Human | Esophagus | ESCC | 3.45e-17 | 4.43e-01 | 0.1149 |
| 126133 | ALDH16A1 | P16T-E | Human | Esophagus | ESCC | 7.69e-07 | 1.35e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALDH16A1 | SNV | Missense_Mutation | c.862G>T | p.Asp288Tyr | p.D288Y | Q8IZ83 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALDH16A1 | SNV | Missense_Mutation | rs754754057 | c.2372C>T | p.Ala791Val | p.A791V | Q8IZ83 | protein_coding | tolerated(0.38) | benign(0.167) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| ALDH16A1 | SNV | Missense_Mutation | rs781770831 | c.1001N>A | p.Arg334Gln | p.R334Q | Q8IZ83 | protein_coding | tolerated(0.18) | benign(0.267) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ALDH16A1 | insertion | Nonsense_Mutation | novel | c.2283_2284insGTCTCGAACTCCTGACCTCGCGTGAT | p.Leu762ValfsTer5 | p.L762Vfs*5 | Q8IZ83 | protein_coding | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | ||
| ALDH16A1 | SNV | Missense_Mutation | novel | c.2074N>A | p.Val692Ile | p.V692I | Q8IZ83 | protein_coding | tolerated(0.16) | possibly_damaging(0.509) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ALDH16A1 | SNV | Missense_Mutation | rs779298390 | c.632C>A | p.Ala211Asp | p.A211D | Q8IZ83 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ALDH16A1 | SNV | Missense_Mutation | rs746123884 | c.533N>T | p.Ser178Phe | p.S178F | Q8IZ83 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| ALDH16A1 | SNV | Missense_Mutation | novel | c.2338G>A | p.Glu780Lys | p.E780K | Q8IZ83 | protein_coding | tolerated(0.18) | benign(0) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ALDH16A1 | SNV | Missense_Mutation | rs768690823 | c.1382N>T | p.Ser461Leu | p.S461L | Q8IZ83 | protein_coding | deleterious(0) | benign(0.024) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ALDH16A1 | SNV | Missense_Mutation | rs140469932 | c.1717N>A | p.Ala573Thr | p.A573T | Q8IZ83 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3939-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |